Iovance to host conference call Thursday to highlight positive lifileucel results in mNSCLC

Iovance Biotherapeutics will host a conference call and live audio webcast on Thursday, October 29, 2026 at 8:30 a.m. ET to highlight positive results for one-time lifileucel TIL therapy from the IOV-LUN-202 Phase 2 registrational cohorts in previously treated nonsquamous metastatic non-small cell lung cancer.

Detected & updated continuously · Source: Nebula